A Phase 3 interventional study of Zavegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 61 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.
Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 3 in phase 3, and was the 6th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States
Ages 6–11
Mayo Clinic · Sites in United States
Ages 18+
American Center for Psychiatry and Neurology
Ages 18+
By country, each count listing its studies:
zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2019; this study’s year is marked. 2 started in 2023.
This study's enrollment of 1,414 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 225 across the 12 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 12th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 in phase 3, and was the 32nd registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing zavegepant in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401642Mayo ClinicEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | 2027-03 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
| NCT06995729PfizerA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing zavegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect.
This study is seeking for participants who:
The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity.
The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults.
Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with minimum 1 year history of migraine (with or without aura) prior to the Screening Visit, consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zavegepant intranasal 10 mg
Drug: Zavegepant
Placebo
Drug: Placebo
The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
Single dose of matching placebo taken within Treatment Phase.
Percentage of Participants With Pain Freedom at 2 Hours Post-dose
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: At 2 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
MBS was selected from nausea, phonophobia or photophobia before dosing by the participants. In this outcome measure, percentage of participants who recorded an MBS (present) before dosing and did not have the MBS (absent) at the time of evaluation (i.e., 2 hours post-dose) were reported.
Time frame: At 2 hours post-dose
Percentage of Participants With Pain Relief at 15 Minutes Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: At 15 minutes post-dose
Percentage of Participants With Pain Relief at 30 Minutes Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: At 30 minutes post-dose
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: At 2 hours post-dose
Percentage of Participants Who Returned to Normal Function at 2 Hours Post-dose
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 2 hours post-dose) were reported.
Time frame: At 2 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
Time frame: From 2 hours post-dose to 24 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
Time frame: From 2 hours post-dose to 48 hours post-dose
Percentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 30 minutes post-dose) were reported.
Time frame: At 30 minutes post-dose
Percentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 60 minutes post-dose) were reported.
Time frame: At 60 minutes post-dose
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Freedom from phonophobia was defined as phonophobia absent at specified time point for participants with the phonophobia present at the time of dosing. In this outcome measure, percentage of participants who had phonophobia at the time of dosing and then recorded phonophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.
Time frame: At 2 hours post-dose
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Freedom from photophobia was defined as photophobia absent at specified time point for participants with the photophobia present at the time of dosing. In this outcome measure, percentage of participants who had photophobia at the time of dosing and then recorded photophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.
Time frame: At 2 hours post-dose
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Freedom from nausea was defined as nausea absent at specified time point for participants with the nausea present at the time of dosing. In this outcome measure, percentage of participants who had nausea at the time of dosing and then recorded nausea absent at time of evaluation (i.e., 2 hours post-dose) were reported.
Time frame: At 2 hours post-dose
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
Time frame: From 2 hours post-dose to 24 hours post-dose
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
Time frame: From 2 hours post-dose to 48 hours post-dose
Percentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose
Pain relapse was defined as pain intensity of mild, moderate, or severe at any time point after 2 hours to 48 hours post-dose for participants with pain intensity of none at 2 hours post-dose. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: From after 2 hours post-dose to 48 hours post-dose
Percentage of Participants Taking Rescue Medication Within 24 Hours Post-dose
Participants who did not experience relief (pain intensity of none or mild) of their migraine headache at the end of 2 hours post-dose, or the migraine was relieved at 2 hours post-dose, but then recurred to a moderate or severe pain intensity level, were permitted to use the following rescue medications: aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug), acetaminophen up to 1000 mg/day (this included Excedrin Migraine), antiemetics (for example, metoclopramide or promethazine), or baclofen.
Time frame: Within 24 hours post-dose
Percentage of Participants With Pain Relief at 60 Minutes Post-dose
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
Time frame: At 60 minutes post-dose
Percentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 15 minutes post-dose) were reported.
Time frame: At 15 minutes post-dose
Number of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activity/activities of daily living (ADL), causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.
Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Number of Participants With AEs of Moderate or Severe Intensity: Follow-up Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual ADL, causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.
Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Number of Participants With Serious Adverse Events (SAEs): On-Treatment Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.
Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Number of Participants With SAEs: Follow-up Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.
Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Number of Participants With Local Irritation AEs: On-Treatment Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).
Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Number of Participants With Local Irritation AEs: Follow-up Period
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).
Time frame: Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days
Number of Participants With Grade 3 to 4 Hematological Test Abnormalities: On-Treatment Period
Hematological test abnormalities included: anemia, eosinophilia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophils count decreased, platelet count decreased and white blood cell decreased. Only those hematology test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The hematological test abnormalities grade 3 to 4 were graded according to the common terminology criteria for adverse events (CTCAE) version (v) 5.0.
Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
Number of Participants With Grade 3 to 4 Clinical Chemistry Test Abnormalities: On-Treatment Period
Clinical chemistry test abnormalities included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, blood lactate dehydrogenase increased, creatine phosphokinase (CPK) increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia and hyponatremia. Only those clinical chemistry test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The clinical chemistry test abnormalities grade 3 to 4 were graded according to the CTCAE v 5.0.
Time frame: On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days
| Milestone | Zavegepant | Placebo |
|---|---|---|
| Started | 708 | 706 |
| Treated | 678 | 675 |
| Completed | 678 | 673 |
| Not completed | 30 | 33 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Randomized but not treated | 30 | 31 |
| Milestone | Zavegepant | Placebo |
|---|---|---|
| Started | 678 | 675 |
| Completed | 678 | 673 |
| Not completed | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Freedom at 2 Hours Post-dose | 23.2 (20.0 to 26.4) | 14.1 (11.4 to 16.7) |
MBS was selected from nausea, phonophobia or photophobia before dosing by the participants. In this outcome measure, percentage of participants who recorded an MBS (present) before dosing and did not have the MBS (absent) at the time of evaluation (i.e., 2 hours post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose | 52.7 (49.0 to 56.5) | 39.9 (36.2 to 43.6) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 15 Minutes Post-dose | 14.5 (11.8 to 17.1) | 10.9 (8.5 to 13.3) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 30 Minutes Post-dose | 30.3 (26.8 to 33.7) | 24.1 (20.8 to 27.3) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 2 Hours Post-dose | 67.2 (63.7 to 70.7) | 51.0 (47.2 to 54.8) |
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 2 hours post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Who Returned to Normal Function at 2 Hours Post-dose | 38.0 (34.2 to 41.9) | 24.4 (21.0 to 27.8) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose | 55.8 (52.1 to 59.6) | 39.8 (36.1 to 43.5) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). This outcome of sustained pain relief was defined as pain intensity being mild or none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose | 53.3 (49.6 to 57.1) | 38.6 (34.9 to 42.3) |
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 30 minutes post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Who Returned to Normal Function at 30 Minutes Post-dose | 8.3 (6.1 to 10.5) | 6.3 (4.4 to 8.2) |
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 60 minutes post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Who Returned to Normal Function at 60 Minutes Post-dose | 22.3 (19.0 to 25.6) | 14.6 (11.8 to 17.4) |
Freedom from phonophobia was defined as phonophobia absent at specified time point for participants with the phonophobia present at the time of dosing. In this outcome measure, percentage of participants who had phonophobia at the time of dosing and then recorded phonophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose | 52.1 (47.4 to 56.9) | 36.3 (31.8 to 40.9) |
Freedom from photophobia was defined as photophobia absent at specified time point for participants with the photophobia present at the time of dosing. In this outcome measure, percentage of participants who had photophobia at the time of dosing and then recorded photophobia absent at the time of evaluation (i.e., 2 hours post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose | 49.1 (44.5 to 53.7) | 38.0 (33.4 to 42.5) |
Freedom from nausea was defined as nausea absent at specified time point for participants with the nausea present at the time of dosing. In this outcome measure, percentage of participants who had nausea at the time of dosing and then recorded nausea absent at time of evaluation (i.e., 2 hours post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose | 64.2 (59.9 to 68.6) | 51.3 (46.8 to 55.8) |
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 24 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose | 17.7 (14.8 to 20.6) | 11.2 (8.8 to 13.6) |
Pain freedom was defined as pain intensity being none at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe). Sustained pain freedom was defined as pain intensity being none at all time points from 2 to 48 hours post-dose with missing data \<=1 time point from 3 to 8 hours post-dose.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose | 17.3 (14.4 to 20.1) | 11.1 (8.7 to 13.4) |
Pain relapse was defined as pain intensity of mild, moderate, or severe at any time point after 2 hours to 48 hours post-dose for participants with pain intensity of none at 2 hours post-dose. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relapse at Any Time Point After 2 Hours Post-dose to 48 Hours Post-dose | 29.3 (22.2 to 36.4) | 22.3 (13.9 to 30.8) |
Participants who did not experience relief (pain intensity of none or mild) of their migraine headache at the end of 2 hours post-dose, or the migraine was relieved at 2 hours post-dose, but then recurred to a moderate or severe pain intensity level, were permitted to use the following rescue medications: aspirin, ibuprofen, naproxen (or any other type of nonsteroidal anti-inflammatory drug), acetaminophen up to 1000 mg/day (this included Excedrin Migraine), antiemetics (for example, metoclopramide or promethazine), or baclofen.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Taking Rescue Medication Within 24 Hours Post-dose | 17.1 (14.3 to 20.0) | 24.4 (21.1 to 27.6) |
Pain relief was defined as pain intensity being none or mild at the specified time point. Participants recorded their headache pain intensity using 4-point numeric rating scale (0= none, 1= mild, 2= moderate, 3= severe).
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 60 Minutes Post-dose | 48.6 (44.8 to 52.4) | 41.9 (38.1 to 45.6) |
Participants recorded their functional disability level using a 4-point numeric rating scale (0= normal, 1= mildly impaired, 2= severely impaired, 3= required bedrest). In this outcome measure, percentage of participants who had functional disability (mildly impaired, severely impaired, or required bedrest) at the time of dosing and then returned to normal function level at the time of evaluation (i.e., 15 minutes post-dose) were reported.
| Percentage of participants | Zavegepant | Placebo |
|---|---|---|
| Percentage of Participants Who Returned to Normal Function at 15 Minutes Post-dose | 4.1 (2.5 to 5.6) | 2.7 (1.4 to 4.0) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activity/activities of daily living (ADL), causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.
| Participants | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period |
|---|---|---|
| Number of Participants With Adverse Events (AEs) of Moderate or Severe Intensity: On-Treatment Period | 9 | 6 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Moderate AE: A type of AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual ADL, causing discomfort, but posed no significant or permanent risk of harm to the research participant. Severe AE: A type of AE that interrupted usual ADL, or significantly affected clinical status, or might have required intensive therapeutic intervention.
| Participants | Zavegepant: Follow-up Period | Placebo: Follow-up Period |
|---|---|---|
| Number of Participants With AEs of Moderate or Severe Intensity: Follow-up Period | 8 | 3 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.
| Participants | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs): On-Treatment Period | 2 | 1 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic, or other situations.
| Participants | Zavegepant: Follow-up Period | Placebo: Follow-up Period |
|---|---|---|
| Number of Participants With SAEs: Follow-up Period | 3 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).
| Participants | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period |
|---|---|---|
| Number of Participants With Local Irritation AEs: On-Treatment Period | 41 | 6 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Local irritation AEs were associated with intranasal administration of study intervention (e.g., dysgeusia, nasal discomfort, oropharyngeal pain, throat irritation, and laryngeal discomfort).
| Participants | Zavegepant: Follow-up Period | Placebo: Follow-up Period |
|---|---|---|
| Number of Participants With Local Irritation AEs: Follow-up Period | 0 | 0 |
Hematological test abnormalities included: anemia, eosinophilia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophils count decreased, platelet count decreased and white blood cell decreased. Only those hematology test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The hematological test abnormalities grade 3 to 4 were graded according to the common terminology criteria for adverse events (CTCAE) version (v) 5.0.
| Participants | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period |
|---|---|---|
| Anemia | 1 | 0 |
| Lymphocyte count decreased | 1 | 0 |
| Neutrophil count decreased | 2 | 2 |
Clinical chemistry test abnormalities included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, blood lactate dehydrogenase increased, creatine phosphokinase (CPK) increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia and hyponatremia. Only those clinical chemistry test categories in which at least one participant in at least one reporting arm experienced a Grade 3 or Grade 4 abnormality were reported in this outcome measure. The clinical chemistry test abnormalities grade 3 to 4 were graded according to the CTCAE v 5.0.
| Participants | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period |
|---|---|---|
| CPK increased | 4 | 4 |
| Hyperglycemia | 1 | 0 |
Collected over On-treatment period: On-treatment period was from the administration of study intervention and through the EOT visit, up to 10 days; Follow-up period: Follow-up period was after the EOT visit and through the follow-up visit, up to 33 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant: On-Treatment Period | 0/678 (0%) | 2/678 (0.3%) | 53/678 (7.8%) |
| Placebo: On-Treatment Period | 0/675 (0%) | 1/675 (0.1%) | 23/675 (3.4%) |
| Zavegepant: Follow-up Period | 0/678 (0%) | 3/678 (0.4%) | 0/678 (0%) |
| Placebo: Follow-up Period | 0/675 (0%) | 0/675 (0%) | 0/675 (0%) |
| Event | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period | Zavegepant: Follow-up Period | Placebo: Follow-up Period |
|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/678 | 1/675 | 0/678 | 0/675 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/678 | 0/675 | 1/678 | 0/675 |
| Neck massMusculoskeletal and connective tissue disorders | 1/678 | 0/675 | 0/678 | 0/675 |
| Cerebral infarctionNervous system disorders | 0/678 | 0/675 | 1/678 | 0/675 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/678 | 0/675 | 0/678 | 0/675 |
| EndometriosisReproductive system and breast disorders | 0/678 | 0/675 | 1/678 | 0/675 |
| Event | Zavegepant: On-Treatment Period | Placebo: On-Treatment Period | Zavegepant: Follow-up Period | Placebo: Follow-up Period |
|---|---|---|---|---|
| DysgeusiaNervous system disorders | 25/678 | 2/675 | 0/678 | 0/675 |
| Urinary tract infectionInfections and infestations | 14/678 | 11/675 | 0/678 | 0/675 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 12/678 | 1/675 | 0/678 | 0/675 |
| Upper respiratory tract infectionInfections and infestations | 9/678 | 9/675 | 0/678 | 0/675 |
Participants who were enrolled and took study intervention (Zavegepant or Placebo) were included in baseline analysis population.
| Age, Continuous(Years) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Mean | 39.0 ± 9.92 | 39.5 ± 10.49 | 39.3 ± 10.21 |
| Sex: Female, Male(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Female | 535 | 510 | 1045 |
| Male | 143 | 165 | 308 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 678 | 675 | 1353 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 678 | 675 | 1353 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2023 to primary completion in May 2025, 18 months.
Results were first posted in May 2026, 11 months after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 18 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant